Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
PHASE3ENROLLING_BY_INVITATION
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema.
Study details:
The study consists of a Screening Period during which eligibility is confirmed (only for participants not rolling over within 28 days from a previous deucrictibant prophylactic study), a Treatment Period in which participants will receive open-label deucrictibant extended-release tablet once daily for approximately 130 weeks, followed by an End of Study visit after maximum 4 weeks. Participants will undergo regular safety (e. g.
lab draws) and efficacy assessments, will complete an electronic diary daily, and also complete questionnaires at predefined timepoints during the study.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
- Provision of written informed consent/assent.
- Male or female, aged ≥12 years at the time of providing written informed consent/assent.
- Diagnosis of hereditary angioedema (HAE)
- For participants that did not participate in a previous deucrictibant prophylactic study: history of at least 1 attack in the last 3 consecutive months prior to Screening
- Reliable access and ability to use standard of care on-demand treatments to effectively manage acute HAE attacks.
- Willing and able to adhere to all protocol requirements, including eDiary and ePRO data recording.
- Female participants of childbearing must agree to the protocol specified pregnancy testing and contraception methods.
Exclusion criteria
- Any diagnosis of angioedema other than HAE
- Participation in a clinical study with any other investigational drug within the last 30 days or within 5 half-lives of the investigational drug at ICF signature (whichever is longer)
- Prior gene therapy for any indication at any time
- Participants who discontinued from previous studies with deucrictibant prophylactic and/or on-demand treatment due to safety reasons or compliance issues that, in the opinion of the Investigator, would interfere with the participant's safety or compliance to participate in the study
- Exposure to ACE inhibitors or any estrogen-containing medications with systemic absorption within 4 weeks of Screening
- Use of prophylactic treatment for HAE within 2 weeks of Screening for C1INH, oral kallikrein inhibitors, or anti-fibrinolytics; within 4 weeks of Screening for attenuated androgens; within 5 half-lives of Screening for monoclonal antibodies, or within 7 days of Screening for short-term prophylaxis
- Any females who are pregnant, plan to become pregnant, or are currently breast-feeding
- Abnormal hepatic function
- Moderate or severe renal impairment
- Any clinically significant comorbidity or systemic dysfunction that would interfere with the participant's safety or ability to participate in the study.
- History of alcohol or drug abuse within the previous year, or current evidence of substance dependence or abuse
- Use of medications that are moderate and strong inhibitors or strong inducers of CYP3A4 within the last 30 days or within 5 half-lives (whichever is longer) of the time of randomization
- Known hypersensitivity to deucrictibant or any of the excipients of the study drug
Eligibility
Age eligible for study : NA
Healthy volunteers accepted : No
Gender eligible for study: ALL
Things to know
Study dates
Study start:
Primary completion:
Study completion finish:
Study type
TREATMENT
Phase
- PHASE3
Study ID
NCT06679881
Intervention or treatment
DRUG: Deucrictibant
Conditions
- Hereditary Angioedema (HAE)
You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.
Research sites nearby
Closest Location:
Study Site
Select from list below to view details:
Study Site
Melbourne, Australia
Study Site
Melbourne, Australia
Study Site
Perth, Australia
Loading map...
Who is running the clinical trial?
PNB
Pharvaris Netherlands B.V.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
|---|---|
EXPERIMENTAL: Deucrictibant
| Drug: Deucrictibant |
What is the study measuring?
Primary Outcome
| Measure | Description | Time Frame |
|---|---|---|
| Treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), adverse events of special interest (AESIs), and TEAEs leading to study drug discontinuation | Not Specified | Up to 138 weeks |
| Change in heart rate | Not Specified | Up to 138 weeks |
| Change in blood pressure | Not Specified | Up to 138 weeks |
| Change in body temperature | Not Specified | Up to 138 weeks |
| Change in clinical laboratory tests from baseline | Hematology, blood chemistry, and urinalysis. Descriptive in nature, no formal statistical hypothesis testing will be performed. | Up to 138 weeks |
| Change in electrocardiograms (ECGs) from baseline | Digital triplicate 12-lead ECG. Descriptive in nature, no formal statistical hypothesis testing will be performed. | Up to 138 weeks |
Secondary Outcome
| Measure | Description | Time Frame |
|---|---|---|
| Time-normalized number of Investigator-confirmed HAE attacks during the Treatment Period | Not Specified | 130 weeks |
| Time-normalized number of Investigator-confirmed HAE attacks treated with on-demand medication during the Treatment Period | Not Specified | 130 weeks |
| Time-normalized number of Investigator-confirmed moderate or severe HAE attacks during Treatment Period | Not Specified | 130 weeks |
| Time-normalized number of Investigator-confirmed severe HAE attacks during the Treatment Period | Not Specified | 130 weeks |
| Proportion of time without angioedema symptoms during the Treatment Period | Not Specified | 130 weeks |
| Patient reported outcome: Angioedema Quality of Life (AE-QoL) questionnaire | The AE-QoL is a short 17-item questionnaire designed to retrospectively assess HRQoL, with a recall period of 4 weeks. Its results can be displayed as a total score or as 4 domain scores. The scores range from 0 to 100, after linear transformation of raw values, with higher scores indicating higher HRQoL impairment. | 130 weeks |
| Patient reported outcome: Patient Global Assessment of Change (PGA-Change) | PGA-Change assesses on a 5-point scale how the participant's QoL has been impacted by HAE since start taking the study drug. | 130 weeks |
| Patient reported outcome: Angioedema Control Test 4-week version (AECT-4wk) | AECT-4wk measures disease control retrospectively, it comprises 4 questions over a 4-week recall period. Scores for the responses in the AECT range from 0 to 16, with higher scores indicating better disease control (≤ 9 poorly controlled; ≥ 10 well controlled). | 130 weeks |
| Patient reported outcome: Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) | WPAI-SHP is a questionnaire assessing how a health condition impacts a person's ability to work and do regular activities and it includes 4 domains. Scores indicate the percentage of time the patient missed work or was less productive owing to HAE-related complications. | Up to 134 weeks |
| Patient reported outcome: Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) | TSQM-9 is a 9-item questionnaire evaluating patient treatment satisfaction and it includes 3 domains. Scoring is by domain and each domain score is computed by summing the individual TSQM items in each domain and then transforming the composite score into a value ranging from 0 to 100, with higher scores indicating higher satisfaction. | Up to 134 weeks |
| Pharmacokinetics [PK]: Deucrictibant plasma concentration pre-dose (Ctrough) | Not Specified | 130 weeks |
Are you running this trial?If you're a clinic or sponsor, you can claim this study.
References
Clinical Trials Gov: Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEOther trials to consider
Loading suggested trials...
